Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...
Psychedelic Medicines Part 1
Patenting known and new chemical entities
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Alex May
Alex is an intellectual property disputes lawyer with twelve years’ experience and a track record of obtaining successful outcomes for clients. He specialises in advising pharmaceutical companies on patent litigation and related matters and has a technical background in genetics.
Alex has represented some of the largest pharmaceutical companies in the world in patent disputes relating to blockbuster antiviral, autoimmunity and chemotherapy medicines.
See Alex's full profile
Medicinal Cannabis in Australia | Part 1: Available Products
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal...
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
Pearce IP BioBlast®: w/e 8 April 2022
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed
In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator...
AU Budget 22-23: Highlights for Health, Pharma/Biopharma, Life Sciences & Agribusiness
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make...
High Court Puts The Brakes On Damages Recovery During Patent Term Extension
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week...
Reminder – new .au domain names coming to Australia from 24 March 2022
Priority given to owners of corresponding Australian domain names in the .au race
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence...
Strategies for generic/biosimilar market entry in Australia
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...
Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its...
New .au domain names coming to Australia
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid: a Question of Scale
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when...
Let the applicant beware!
Misrepresentations are not just limited to examples
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
Galvanising your exclusive licence: take-home messages from recent case law
Questions to be answered by the High Court in the Lundbeck Appeal: Part Two
Recent decisions of the Australian Federal Court reinforce the need for exclusive patent licences to include all...
How medicine repurposing could unravel the pharma industry in Australia
TGA seeks consultation on issues relating to the registration of off-label medicines: Part 2
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper...